4.7 Article

p66ShcA potentiates the cytotoxic response of triple-negative breast cancers to PARP inhibitors

Journal

JCI INSIGHT
Volume 6, Issue 4, Pages -

Publisher

AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/jci.insight.138382

Keywords

-

Funding

  1. Fonds de recherche du Quebec -Sante (FRQS) Senior Research Scholar Award
  2. FRQS Junior 2 award
  3. Canadian Cancer Society [703826]
  4. Oncopole EMC2 grant
  5. Canadian Institutes of Health (CIHR) [PJT-168832, PJT-159663, MOP133449]
  6. McGill Integrated Cancer Research Training Program studentship
  7. Canada Graduate Scholarships-Master's Program (CIHR), Cole Foundation Fellowship
  8. CIHR Doctoral Research Award
  9. Next Generation of Scientist award from the Cancer Research Society

Ask authors/readers for more resources

TNBC lacks effective targeted therapies, and PARP inhibitors are being tested as a potential treatment option. Studies suggest that increasing ROS levels can enhance sensitivity to PARP inhibitors, and the p66ShcA protein has been found to potentiate the synergy between PARP inhibitors and doxorubicin in TNBCs.
Triple-negative breast cancers (TNBCs) lack effective targeted therapies, and cytotoxic chemotherapies remain the standard of care for this subtype. Owing to their increased genomic instability, poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) are being tested against TNBCs. In particular, clinical trials are now interrogating the efficacy of PARPi combined with chemotherapies. Intriguingly, while response rates are low, cohort of patients do respond to PARPi in combination with chemotherapies. Moreover, recent studies suggest that an increase in levels of ROS may sensitize cells to PARPi. This represents a therapeutic opportunity, as several chemotherapies, including doxorubicin, function in part by producing ROS. We previously demonstrated that the p66ShcA adaptor protein is variably expressed in TNBCs. We now show that, in response to therapy-induced stress, p66ShcA stimulated ROS production, which, in turn, potentiated the synergy of PARPi in combination with doxorubicin in TNBCs. This p66ShcA-induced sensitivity relied on the accumulation of oxidative damage in TNBCs, rather than genomic instability, to potentiate cell death. These findings suggest that increasing the expression of p66ShcA protein levels in TNBCs represents a rational approach to bolster the synergy between PARPi and doxorubicin.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available